Clinical trials: Depression NOS
Opioid Overdose
Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg
The purpose of this study is to determine the pharmacodynamics (change in minute ventilation) of nalmefene when given as an autoinjector intramuscularly (IM; into the thigh) compared to naloxone when given intranasally (IN; into…
- Trial name
- NCT06719986
- Testing
- Nalmefene HCl injection, Naloxone HCl intranasal
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Purdue Pharma LP
Mild Cognitive Impairment
A Retrospective Analysis of Cerefolin NAC® in Cognitively Impaired Patients
This retrospective analysis of de-identified data from 700 charts of consecutive patients from this patient population is to investigate the prevalence of hyperhomocysteinemia and associated metabolic abnormalities in this…
- Trial name
- NCT01594541
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- Pamlab, Inc.
Major Depressive Disorder, Depression
TC-5214 as add-on the Treatment of Major Depressive Disorder
This is a multi-center, double blind, randomized, placebo-controlled, parallel group, flexible dose titration study conducted in centers in the USA and India.
- Trial name
- NCT00692445
- Testing
- TC-5214 + citalopram
- Where
- 27 sites in United States, India
- Volunteers
- 574 people
- Sponsor
- Targacept Inc.
Major Depressive Disorder
Trazodone Once a Day in Major Depression Disorder
The study objective is to evaluate the efficacy and safety of trazodone OAD vs venlafaxine extended release (venlafaxine XR) after an 8-week treatment period in patients with major depressive disorder.
- Trial name
- NCT02086929
- Testing
- Trazodone, Venlafaxine
- Where
- 32 sites in Austria, Czechia and 4 more
- Volunteers
- 364 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Major Depressive Disorder
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
- Trial name
- NCT06911112
- Testing
- NBI-1065845
- Where
- 39 sites in United States, Bulgaria and 3 more
- Volunteers
- 200 people
- Sponsor
- Neurocrine Biosciences
Major Depressive Disorder
Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)
The study will assess efficacy, safety and tolerability of 0.5 mg/day and 1 mg/day of sublingual (under the tongue) formulation of agomelatine in patients with Major Depressive Disorder.
- Trial name
- NCT01110902
- Testing
- Agomelatine (AGO178C)
- Where
- 45 sites in United States, Puerto Rico
- Volunteers
- 589 people
- Sponsor
- Novartis Pharmaceuticals
Bipolar Depression
Safety and Efficacy Study of Deep Transcranial Magnetic Stimulation in Bipolar Depression
The purpose of the study is to evaluate the efficacy and safety of H1-Coil deep brain rTMS in subjects with bipolar depression, taking mood stabilizers and previously unsuccessfully treated with antidepressant medications.
- Trial name
- NCT01566591
- Testing
- Deep TMS Treatment
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 120 people
- Sponsor
- Brainsway
Depressive Disorder, Major, Suicidal Ideation
A Study to Describe Routine Treatment Pathways in Participants With Major Depression and Active Suicidal Ideation With Intent in Italy
The purpose of the study is to describe the pharmacological and non-pharmacological treatment utilization pathways in Italian routine clinical practice of participants with Major Depressive Disorder (MDD) and active suicidal…
- Trial name
- ARIANNA (NCT04463108)
- Testing
- No Intervention
- Where
- 24 sites in Italy
- Volunteers
- 136 people
- Sponsor
- Janssen-Cilag S.p.A.
Major Depressive Disorder
Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder
This study is designed to evaluate the safety and efficacy of synchronized transcranial magnetic stimulation (sTMS) using the NeoSync EEG Synchronized TMS device (NEST) in subjects with Major Depressive Disorder.
- Trial name
- NEST-MDD (NCT01370733)
- Testing
- NEST-1 (NeoSync EEG Synchronized TMS)
- Where
- 18 sites in United States
- Volunteers
- 202 people
- Sponsor
- Wave Neuroscience
Major Depressive Disorder
A Safety and Efficacy Study of Escitalopram on Acute Treatment of Severe Depression
The purpose of this study is to evaluate the efficacy and safety of escitalopram treatment in participants with severe major depressive disorder (MDD [marked depression appearing in the involution period and characterized by…
- Trial name
- NCT01814085
- Testing
- Escitalopram
- Where
- 6 sites in China
- Volunteers
- 225 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Depression
Japanese Phase 1 Multiple Ascending Dose (MAD) Study
The purpose of this clinical study is to assess the safety and tolerability of multiple oral doses of BMS-820836 in healthy Japanese subjects and Japanese patients with depression.
- Trial name
- NCT01396252
- Testing
- BMS-820836
- Where
- Japan
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Arrhythmia, Quality of Life
Psychosomatic Effects of Implantable Cardioverter Defibrillator With Home Monitoring Function (QUANTUM)
Quality of life (QOL) and psychological well-being of patients with implantable cardioverter-defibrillators (ICDs) are significantly influenced by the experience of shock therapies.
- Trial name
- NCT00325221
- Testing
- HM on, HM Off
- Where
- 7 sites in Austria, Germany and 1 more
- Volunteers
- 148 people
- Sponsor
- Biotronik SE & Co. KG
Depression
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
The purpose of the study is to evaluate the efficacy of study drug (BMS-820836) as compared with continued Duloxetine/Escitalopram in the treatment of patients with treatment resistant depression (TRD).
- Trial name
- NCT01369095
- Testing
- Duloxetine, Escitalopram, BMS-820836
- Where
- 93 sites in United States, Argentina and 10 more
- Volunteers
- 976 people
- Sponsor
- Bristol-Myers Squibb
Psychotic Depression, Severe Major Depression With Psychotic Features
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
Approximately 450 patients will be randomized to receive mifepristone or placebo for 7 days followed by antidepressant. The purpose is to compare the efficacy of mifepristone followed by antidepressant versus placebo followed by…
- Conditions
- Psychotic Depression, Severe Major Depression With Psychotic Features, Psychosis
- Trial name
- NCT00637494
- Testing
- mifepristone
- Where
- 42 sites in United States
- Volunteers
- 292 people
- Sponsor
- Corcept Therapeutics
Major Depressive Disorder
Cranial Electrotherapy Stimulation for the Treatment of Major Depressive Disorder in Adults
This study is designed to evaluate the safety and efficacy of the Fisher Wallace Stimulator FW-200 to deliver Cranial Electrotherapy Stimulation (CES) for the treatment of moderate to severe Major Depressive Disorder (MDD) in…
- Trial name
- CES-MDD (NCT05384041)
- Testing
- Fisher Wallace Cranial Electrotherapy Stimulator (Active Device)
- Where
- United States
- Volunteers
- 255 people
- Sponsor
- Fisher Wallace Laboratories
Major Depressive Disorder
Brainsway DTMS for Treatment of MDD Using iTBS
The safety and effectiveness of the BrainsWay deep transcranial magnetic stimulation (DTMS) device for the intended use of Major Depressive Disorder (MDD) using the intermittent theta-burst (iTBS) stimulation protocol will be…
- Trial name
- NCT04679753
- Testing
- Brainsway DTMS with intermittent Theta Burst Stimulation (iTBS), Brainsway DTMS with High Frequency (HF) Stimulation
- Where
- Canada
- Volunteers
- 177 people
- Sponsor
- Brainsway
Depression
Internet Program for Workers With Subthreshold Depression
Depression is one of the most prevalent mental disorders to afflict adults. It seriously impacts role functioning and often takes a recurrent or chronic course.
- Trial name
- WorkDep (NCT02335554)
- Testing
- MoodHacker, Alternative Care
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Oregon Center for Applied Science, Inc.
Early Onset Alzheimer Disease, Mild Cognitive Impairment
Reference Database & Longitudinal Registry of the Normal and Pathological Aging Brain
Establishment of a BNA reference database for the Adult and Elderly Population. Hypothesis-generating study designed to collect data that will aid in future scientific and engineering exploration of correlations between clinical…
- Conditions
- Early Onset Alzheimer Disease, Mild Cognitive Impairment, Depression, Aging
- Trial name
- (BNA™) (NCT02875496)
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- ElMindA Ltd
PTSD, Anxiety
Exploring Medically Perceived Benefits, Use and Interest in Psychedelics and Cannabinoids
The primary objective of this study is to collect insights from first responders and military personnel on their need for, use of, and interest in physical and/or mental health medical marijuana or psychedelic-assisted therapy…
- Conditions
- PTSD, Anxiety, Anxiety Disorders, Depression
- Trial name
- EMPOWER (NCT04965740)
- Testing
- Cannabis
- Where
- Canada
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Empower Research Inc
Depression, Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women
Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). This study will investigate the safety, efficacy, and tolerability of DVS SR versus escitalopram in women with major…
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- NCT00406640
- Testing
- Desvenlafaxine succinate sustained-release (DVS SR), Escitalopram
- Where
- 70 sites in United States, Argentina and 4 more
- Volunteers
- 595 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer